{"title":"Finerenon kann das kardiovaskuläre Risiko bei Typ-2-Diabetes modifizieren","authors":"V. Pavlicek","doi":"10.1007/s11428-023-01080-x","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":29762,"journal":{"name":"Diabetologie","volume":"19 1","pages":"786 - 788"},"PeriodicalIF":0.3000,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11428-023-01080-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}